**Splendid Medien AG** 

WKN: 727950 | ISIN: DE0007279507 | Bloomberg: SPM GY

# 2019 marked by write-offs

**Book value adjustments in film library:** Splendid announced that the book values of their film library have to be adjusted, which lead to a special write-off in the amount of EUR 8.4m. Additionally, the goodwill value of splendid studios were lowered by EUR 1m (previously: EUR 4.9m). All in all, write-offs amount to EUR 9.4m in 2019.

**New EBIT guidance 2019:** The book value adjustments, the revaluation of goodwill and the reduced sales expectation accordingly led to an adjustment of the EBIT expectation in the 2019 financial year. The EBIT previously forecasted in a range of EUR 1.0m to EUR 3.0m will not be achieved. The Management Board now expects EBIT for the year as a whole to be in the range of EUR -9.0m to EUR -10.5m.

**New sales guidance 2019:** In addition, the Management Board expects that the Group sales forecast for 2019 as a whole in the range of EUR 51m to EUR 55m will also no longer be achieved. Instead, the Management Board expects consolidated sales for the year as a whole to range between EUR 47m and EUR 51m.

**Updated estimates for 2019e:** We now forecast revenues of EUR 47.2m and an EBIT of EUR -10.1m for 2019e. As we had already pointed out in our initial note, flops in Theatrical and Home Entertainment releases can lead to high volatility both in sales and on EBIT level, which now happened.

**HOLD recommendation; new TP of EUR 1.00/share:** The company plans to invest in a broad portfolio of less capital-intensive films in the future. In this way, the company is deviating somewhat from its previous strategy, which in our view limits visibility. We have therefore adjusted our estimates for the next 2 years conservatively. Splendid needs good news/films in order to give the share a positive momentum again.

FY End: 31.12;.in EURm	CAGR (18-21e)	2016	2017	2018	2019e	2020e	2021e
Turnover	-1.1%	51.9	53.0	51.7	47.2	47.5	50.0
EBITDA	-2.0%	17.0	15.4	18.7	19.2	17.3	17.6
Margin		32.8%	29.1%	36.1%	40.6%	36.4%	35.1%
EBIT	-51.6%	-1.4	-2.2	2.4	-10.1	-0.6	0.3
Margin		-2.6%	-4.2%	4.7%	-21.3%	-1.2%	0.5%
net result	-173.1%	-3.9	-3.9	1.4	-10.6	-1.2	-0.5
EPS	-173.1%	-0.40	-0.40	0.14	-1.08	-0.12	-0.06
Dividend per share		0.00	0.00	0.00	0.00	0.00	0.00
EV		22.9	24.6	20.8	22.1	17.1	11.4
EV/Sales		0.4	0.5	0.4	0.5	0.4	0.2
EV/EBITDA		1.3	1.6	1.1	1.2	1.0	0.6
P/E		-2.5	-2.5	6.9	-0.9	-8.0	-17.7
Net debt/EBITDA		-0.8	-1.0	-0.6	-0.6	-0.4	-0.1
Source: Splendid Medien, FM	IR .						

Published: 28th August 2019

HOLD

Before: BUY

Price Target EUR 1.00 (1.50) Share price\* EUR 0.99 (+0%)

\*last XETRA closing price

Change	2019e	2020e	2021e
Sales	-12.2%	-17.6%	-14.7%
EBIT	n.m.	n.m.	n.m.
EPS	n.m.	n.m.	n.m.



Source: Factset

#### **Basic share data**

Number of shares (million)	9.8
Free Float (in %)	31%
Market Cap (in million EUR)	9.8
Trading volume (Ø)	5,200
High (EUR, 52 weeks)	1.75
Low (EUR, 52 weeks)	0.95

# Shareholder structure

Andreas R. Klein & Family	59,3%
Josef Siepe	10,1%
Free float	30.6%

# Corporate calendar

H1 19 report	30.09.2019

# **Analyst**

Marcus Silbe, CEFA

marcus.silbe@fmr-research.de +49 (0) 69 - 920 389 12

# Contact

FMR Frankfurt Main Research AG Schillerstrasse 16 60313 Frankfurt am Main Germany

> +49 (0) 69 - 920 389 10 www.fmr-research.de

# In cooperation with:





# Valuation

DCF valuation											
	P	PHASE 1					PHASE 2				PHASE 3
in EURm	2019e	2020e	2021e	2022e	2023e	2024e	2025e	2026e	2027e	2028e	8
Sales	47.2	47.5	50.0	51.0	52.1	53.1	54.2	55.3	56.4	57.5	
Sales grow th YoY in %	-8.8%	0.6%	5.5%	2.0%	2.0%	2.0%	2.0%	2.0%	2.0%	2.0%	
EBIT	-10.1	-0.6	0.3	2.6	2.6	2.7	2.7	2.8	2.8	2.9	
EBIT margin in %	-21.3%	-1.2%	0.5%	5.0%	5.0%	5.0%	5.0%	5.0%	5.0%	5.0%	
Income tax on EBIT	0.5	0.3	0.1	-0.7	-0.7	-0.7	-0.8	-0.8	-0.8	-0.8	
Depreciation and amortisation	29.2	17.8	17.3	17.6	17.6	17.6	17.6	17.6	17.6	17.6	
Change in net working capital Net capital expenditure	-5.0 -14.9	-1.0 -10.6	-0.3 -10.8	-0.2 -17.5	-0.2 -17.5	-0.2 -17.5	-0.2 -17.5	-0.2 -17.5	-0.2 -17.5	-0.2 -17.6	
Free cash flow	-0.2	6.0	6.6	1.8	1.8	1.9	1.9	2.0	2.0	1.9	
Present values	-0.2	5.3	5.3	1.3	1.2	1.1	1.1	1.0	0.9	0.8	10.9
Present value Phase 1 Present value Phase 2	10.4 7.4	95% 26%			Risk free rate		2.0%		arget equity ax shield	ratio	70.0%
Present value Phase 2 Present value Phase 3	7.4 10.9	26% 38%			Equity risk pro Debt risk prer		6.0% 2.0%		ax snieid eta (fundam	nental)	28.0% 1.70
Tresent value i nase s	10.5	3070			CAGR Sales		2.0%		ACC	icital)	9.40%
Total present value	28.7	100%		Ø	Ø EBIT-margi	n Phase 2	5.0%	Te	erminal gr	owth	2.0%
- Net debt	-17.5				Sensitivity analysis						
- Minority interest (est. market value)	0.0				Terminal growth (Phase 3)						
							1.0%	1.5%	2.0%	2.5%	3.0%
Fair value of equity	11.2					3.0%	0.27	0.30	0.35	0.40	0.45
					EBIT	4.0%	0.63	0.68	0.74	0.81	0.89
Number of shares (m)	9.8				margin	5.0%	1.00	1.06	1.14	1.23	1.33
E (EUD)						6.0%	1.36	1.45	1.54	1.64	1.77
Fair value per share (EUR)	1.14			L		7.0%	1.73	1.83	1.93	2.06	2.20



# Appendix

i	n EURm	2016	2017	2018	2019e	2020e	2021
Revenues		51.9	53.0	51.7	47.2	47.5	50.
YoY grow th		-8.6%	2.2%	-2.5%	-8.8%	0.6%	5.5%
Cost of revenues		-38.2	-39.2	-34.9	-28.8	-27.3	-28.
as % of revenues		-73.5%	-73.9%	-67.5%	-61.0%	-57.5%	-56.5%
Gross profit		13.7	13.9	16.8	18.4	20.2	21.
as % of revenues		26.5%	26.1%	32.5%	39.0%	42.5%	43.5%
General & administrative expenses		-7.0	-6.8	-6.6	-6.1	-6.6	-6.
as % of revenues		-13.5%	-12.7%	-12.8%	-13.0%	-14.0%	-13.69
Sales and marketing expenses		-9.7	-10.8	-8.6	-13.0	-14.1	-14.
as % of revenues		-18.7%	-20.4%	-16.6%	-27.5%	-29.8%	-29.49
Other operating income/exenses		1.7	0.8	0.8	0.1	0.0	0.
as % of revenues		3.2%	1.6%	1.6%	0.1%	0.1%	0.19
Reported EBITDA		17.1	14.8	18.7	19.2	17.3	17.
as % of revenues		33.0%	27.9%	36.2%	40.6%	36.4%	35.19
Depreciation and amortisation (incl. PPA)		-18.4	-17.7	-16.3	-29.2	-17.8	-17.
as % of revenues		-35.5%	-33.3%	-31.4%	-61.9%	-37.6%	-34.6%
Reported EBIT		-1.3	-2.9	2.5	-10.1	-0.6	0.
as % of revenues		-2.5%	-5.4%	4.8%	-21.3%	-1.2%	0.5%
Net financial results incl. equity results		-0.6	-0.9	-1.0	-1.0	-1.0	-1.0
EBT (Earnings before income taxes)		-1.9	-3.7	1.5	-11.1	-1.5	-0.
as % of revenues		-3.7%	-7.0%	2.9%	-23.4%	-3.2%	-1.4%
Income taxes		-2.0	-0.1	-0.1	0.5	0.3	0.
as % of EBT		106.3%	3.8%	-6.1%	-4.5%	-20.0%	-20.09
Income from continuing operations		-3.9	-3.9	1.4	-10.6	-1.2	-0.
Income from discontinued operations, net of	of taxes	0.0	0.0	0.0	0.0	0.0	0.0
Net income		-3.9	-3.9	1.4	-10.6	-1.2	-0.
Minorities		0.0	0.0	0.0	0.0	0.0	0.
Net income attributable to shareholders		-3.9	-3.9	1.4	-10.6	-1.2	-0.
Net margin in %		-7.6%	-7.3%	2.7%	-22.4%	-2.5%	-1.19
Shares outstanding (in m)		9.8	9.8	9.8	9.8	9.8	9.8
Basic earnings per share (EUR)		-0.40	-0.40	0.14	-1.08	-0.12	-0.06



IFRS in EURm	2016	2017	2018	2019e	2020e	2021
Assets						
Non-current assets as % of total assets	<b>39.0</b> 57.5%	<b>38.4</b> 60.5%	<b>36.4</b> 57.1%	<b>22.1</b> 45.6%	<b>14.8</b> 31.1%	<b>8.</b> 17.3
Intangible assets (incl. Goodwill)	5.2	5.1	5.1	5.0	5.0	5.
Property, plant and equipment	1.1	1.3	1.3	1.3	1.3	1.
Long-term investments	27.7	26.0	24.5	10.3	3.0	-3.
Income tax claims (incl. Deferred)	4.3	4.5	5.0	5.0	5.0	5.
Other assets	0.6	1.4	0.5	0.5	0.5	0.
Current assets	28.8	25.0	27.3	26.4	32.8	39.
as % of total assets	42.5%	39.5%	42.9%	54.4%	68.9%	82.7
Inventories	2.1	1.7	1.3	1.4	1.4	1.
Accounts receivable	19.2	17.8	19.5	19.7	21.1	22.
Other receivables and other assets	0.0	0.0	0.0	0.0	0.0	0.
Current income tax claims	0.7	0.0	0.1	0.1	0.1	0.
Cash and cash equivalents	6.8	5.6	6.4	5.1	10.2	15.
otal assets	67.8	63.4	63.6	48.5	47.6	47.
Shareholders' equity as % of total equity and liabilities	<b>22.1</b> 32.6%	<b>18.2</b> 28.8%	<b>19.0</b> 29.8%	<b>8.4</b> 17.4%	<b>7.2</b> 15.2%	<b>6</b> . 13.9
	32.6%	28.8%	29.8%	17.4%	15.2%	13.99
Subscribed capital	9.8	9.8	9.8	9.8	9.8	9.
Capital reserve	0.4	0.4	0.4	0.4	0.4	0.
Accumulated and other comprehensive income	11.9	8.1	8.8	-1.7	-2.9	-3.
Treasurey shares	0.0	0.0	0.0	0.0	0.0	0.
Equity attributable to shareholders  Minorities	<b>22.1</b> 0.0	<b>18.2</b> 0.0	<b>19.0</b> 0.0	<b>8.4</b> 0.0	<b>7.2</b> 0.0	<b>6</b> . 0.
Minorities	0.0	0.0	0.0	0.0	0.0	0.
Current liabilities and provisions	39.1	39.6	42.1	37.5	37.9	38.
as % of total equity and liabilities	57.7%	62.5%	66.1%	77.3%	79.5%	80.7
Financial liabilities	16.7	18.7	16.9	16.9	16.9	16.
Advance payments received	2.1	0.0	0.0	0.0	0.0	0.
Accounts payable	13.5	17.2	14.0	9.0	9.1	9.
Tax liabilities	0.0	0.1	0.2	0.2	0.2	0.
Other provisions	4.2	3.6	6.2	6.5	6.8	7.
Other liabilities	2.6	0.0	4.9	4.9	4.9	4.
Non-current liabilities and provisions	6.6	5.5	2.6	2.6	2.6	2.
as % of total equity and liabilities	9.7%	8.7%	4.0%	5.3%	5.4%	5.3
Pension provisions and similar obligations	0.0	0.0	0.0	0.0	0.0	0.
Financial liabilities	3.5	2.3	1.0	1.0	1.0	1.
Deferred tax liabilities	0.1	0.2	0.4	0.4	0.4	0.
Provisions	0.0	0.0	0.0	0.0	0.0	0.
Other liabilities	3.0	3.1	1.2	1.2	1.2	1.



in EURm	2016	2017	2018	2019e	2020e	2021e
Net income	-1.3	-2.9	2.5	-10.1	-0.6	0.3
Depreciation and amortisation	18.4	17.7	16.3	29.2	17.8	17.3
Other transactions incl. non-cash	-1.5	0.1	-0.5	-0.5	-0.7	-0.8
Change in Working Capital	1.0	-1.0	1.3	-5.0	-1.0	-0.3
Cash flow from operating activities	16.6	13.9	19.5	13.7	15.6	16.4
CAPEX	-18.1	-15.6	-15.7	-14.9	-10.6	-10.8
Change in consolidation, net cash	0.0	0.0	0.0	0.0	0.0	0.0
Other investing activities	-3.4	0.0	0.0	0.0	0.0	0.0
Cash flow from investing activities	-21.5	-15.6	-15.7	-14.9	-10.6	-10.8
Change in debt	5.1	0.5	-3.1	0.0	0.0	0.0
Net proceeds from capital increase & right capital & change in capital reserve	0.0	0.0	0.0	0.0	0.0	0.0
Acquisition of treasury shares & minority stakes	0.0	0.0	0.0	0.0	0.0	0.0
Dividend payments	-1.3	0.0	0.0	0.0	0.0	0.0
Other financing activities	0.0	0.0	0.0	0.0	0.0	0.0
Cash flow from financing activities	3.8	0.5	-3.1	0.0	0.0	0.0
Total change in cash and cash equivalents	-1.1	-1.2	0.8	-1.2	5.0	5.7
Effect of exchange rate changes on cash	0.0	0.0	0.0	0.0	0.0	0.0
Other changes in cash and cash equivalents	0.0	0.0	0.0	0.0	0.0	0.0
Cash and cash equivalents at the start of the period	7.8	6.8	5.6	6.4	5.1	10.2
Cash and cash equivalents at year's end	6.8	5.6	6.4	5.1	10.2	15.8



Declaration of liability (disclaimer) and mandatory details pursuant to Section 85 Securities Trading Act (WpHG), EU Market Abuse Regulation (EU Regulation No. 596/2014), Delegated Regulation 2016/958 and Delegated Regulation 2017/565 including details of possible conflicts of interest (disclosures), the author and the responsible supervisory authority

The following details inform the reader about the legal provisions that are to be observed when compiling financial analyses.

#### 1. Declaration of liability

When producing an analysis, we have procured the actual details from the sources available to us that are generally deemed to be reliable. We cannot make any claim regarding the accuracy and completeness of such information. The recommendations and/or prognoses made by us on the basis of these actual details constitute non-binding value judgments made at the time of compilation of the study and represent the opinion of the author. Subsequent changes cannot be taken into account. FMR Frankfurt Main Research AG shall not be liable for damages of any kind in relation to any incomplete or incorrect information and FMR Frankfurt Main Research AG shall not be liable for indirect and/or direct damages and/or consequential damages. In particular, FMR Frankfurt Main Research AG shall not be liable for statements, plans or other details contained in this investment advice in relation to the company being investigated, its affiliated companies, strategies, market and/or competition situation, economic and/or legal framework conditions etc. Although the investment advice was compiled using full diligence, errors or omissions cannot be excluded. FMR Frankfurt Main Research AG, its shareholders and employees shall not be liable for the correctness or completeness of statements, assessments, recommendations or conclusions derived from the information contained in this analysis.

If an investment recommendation is provided in the context of an existing contractual relationship, e.g. financial advice or a similar service, FMR Frankfurt Main Research AG's liability shall be limited to gross negligence and intent. Should key details be omitted, FMR Frankfurt Main Research AG shall be liable for ordinary negligence. The liability of FMR Frankfurt Main Research AG shall be restricted to the amount of typical and foreseeable damages.

The study does not constitute an offer or request to acquire shares. Our information and recommendations in this study do not constitute individual investment advice and may therefore not be suitable, or may only be of limited suitability, for individual investors depending on the specific investment goals, the investment horizon or individual investment situation. With the compilation and distribution of this study we are not engaged in an investment advisor or portfolio management capacity for any persons. This study cannot replace the need for investment advice in any case.

The estimates, particularly prognoses and price expectations, may not be achieved. The work and all parts thereof are protected by copyright. All use outside the scope of copyright law is impermissible and prosecutable. This shall apply in particular to duplications, translations, microfilms, the saving and processing of the entire content or parts of the content on electronic media.

It is possible that shareholders, managers or employees of FMR Frankfurt Main Research AG or its affiliated companies have a position of responsibility in the companies named in the analysis, e.g. as a member of the supervisory board. The opinions contained in this investment advice may be amended without notice. All rights are reserved.

#### 2. Mandatory details

- a) First publication: 28th August 2019,
- b) Time conditions of expected updates: quarterly
- c) Supervisory authority: Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), Lurgiallee 12, 60439 Frankfurt am Main
- d) Previous analyses: No analysis was published in the 12 months before publication of this analysis that contains a recommendation for a specific investment decision which contradicts this analysis.
- e) The analysis was made available to the issuer, to the extent that is legally permissible, before publication and was not amended thereafter.
- f) All prices and price developments listed in the analysis are based on closing prices insofar as no contradictory details were provided about prices and price developments.

# 3. Disclosures

- a) Neither FMR Frankfurt Main Research AG nor an affiliated company, nor any person who contributed to the compilation
- (i.) has an involvement in the share capital of the issuer of at least 5 per cent;
- (ii.) was involved in the management of a syndicate within the past five months that issued financial instruments of the issuer in the context of a public tender;
- (iii.) managed financial instruments of the issuer on a market by means of concluding purchase or sale agreements:



- (iv.) has, within the past twelve months, concluded an agreement regarding services in connection with investment banking business or received a service or performance promise from such agreement, with issuers which either themselves or the financial instruments thereof, are the subject of the financial analysis;
- (v.) is in possession of a net sales or purchase position which exceeds the threshold of 0.5% of the total issued share capital of the issuer;
- (vi.) has concluded an agreement regarding the preparation of investment recommendations with the issuer.
- (vii.) has other significant interests with regard to the company being analysed, for example clients with the company being analysed.

Company Disclosure(s)
Splendid Medien AG -

b) FMR Frankfurt Main Research AG has concluded a cooperation agreement with Oddo Seydler Bank AG, on the basis of which this financial analysis is compiled. Oddo Seydler Bank AG is acting as the agent of the issuer, which is either the subject of the financial analysis itself or its financial instruments are the subject of the financial analysis.

Neither Oddo Seydler Bank AG nor an affiliated company, nor any person who contributed to the compilation

- (i.) has an involvement in the share capital of the issuer of at least 5 per cent;
- (ii.) was involved in the management of a syndicate within the past five months that issued financial instruments of the issuer in the context of a public tender;
- (iii.) managed financial instruments of the issuer on a market by means of concluding purchase or sale agreements:
- (iv.) has, within the past twelve months, concluded an agreement regarding services in connection with investment banking business or received a service or performance promise from such agreement, with issuers which either themselves or the financial instruments thereof, are the subject of the financial analysis;
- (v.) is in possession of a net sales or purchase position which exceeds the threshold of 0.5% of the total issued share capital of the issuer;
- (vi.) has concluded an agreement regarding the preparation of investment recommendations with the issuer.
- (vii.) has other significant interests with regard to the company being analysed, for example clients with the company being analysed.

Company Disclosure(s)

Splendid Medien AG iii, v, vi

Recommendation history over last 12 months:

Date	Recommendation	Share price at publication date	Price target
11.04.2019	BUY	1.30	1.50
28.08.2019	HOLD	0.99	1.00

# 4. Creation and distribution

a) Responsibility for creation and distribution

FMR Frankfurt Main Research AG

Registered office: Frankfurt am Main; Commercial Register No. HRB 113537, Frankfurt am Main district court; Chairman: Marcus Silbe

b) Issuer

Marcus Silbe, Head of Research, Senior Analyst

c) This study may only be used for the internal purposes of the addressee within the EEA or Switzerland.

### 5. Investment recommendation details

Investment recommendation details - stocks:

BUY: In our opinion, the stock will demonstrate an absolute price gain of at least 10 % in a 12-month period.



HOLD: In our opinion, the stock will not exceed or fall below an absolute price gain or loss of 10% in a 12-month period.

Sell: In our opinion, the stock will demonstrate an absolute price loss of at least 10 % in a 12-month period.

#### 6. Sensitivity of the evaluation parameters

The figures from profit and loss calculations, cash flow statements and balance sheets which form the basis of the company evaluation are date-related estimates and therefore subject to risks. These may change at any time without prior notice. Regardless of the evaluation methods used, there are significant risks that the price goal/trend will not be achieved within the expected time frame. The risks include unforeseeable changes with regard to competition pressure, demand for the products of an issuer and the offer situation with respect to materials required for production as well as non-occurrence of the assumed development. Such deviations may be the result of changes relating to technology and changes relating to the economy, legal situation and exchange rates. No claim is made that this statement of evaluation methods and risk factors is complete.

#### 7. Key sources of information

We have acquired the information upon which this document is based from sources that we consider in principle to be reliable. However, we have not verified all this information. Therefore, we cannot guarantee or ensure the accuracy, completeness or correctness of the information or opinions contained in this document. National and international media and information services (e.g. Factset, Bloomberg etc.), the financial press (e.g. BörsenZeitung, FAZ, Handelsblatt, Wallstreet Journal, etc.), specialist press, published statistics, the internet, as well as publications, details and information of the issuer that is the subject of the analysis.

#### 8. Summary of the basis for evaluation

Individual issuers: Current and recognised evaluation methods (e.g. DCF method and Peer Group Analysis) are used for company analysis purposes. The DCF method calculates the value of the issuer based on the sum of the discounted cash flows, i.e. the cash value of the future cash flows of the issuer. The value is therefore determined on the basis of expected future cash flows and the applied discount rate. In Peer Group Analysis, issuers listed on the stock exchange are evaluated by comparing ratios (e.g. price/profit ratio, Enterprise Value/turnover, Enterprise Value/EBITDA, Enterprise Value/EBIT). The comparability of the ratios is primarily determined with reference to the business activity and economic prospects.

# 9. Internal organisational and regulatory measures for the prevention or management of conflicts of interest

Employees of FMR Frankfurt Main Research AG who are involved with the compilation and/or presentation of financial analyses are subject to the internal compliance regulations. The internal compliance regulations correspond to the provisions of the directive for the substantiation of the organisational obligations of investment service companies pursuant to Section 80 Securities Trading Act and EU/ESMA legislation on the basis of the Market Abuse Regulation.

The analysts of FMR Frankfurt Main Research AG do not receive any direct or indirect remuneration from the investment banking business of FMR Frankfurt Main Research AG.

On acceptance of the financial analysis, the recipient accepts that the above restrictions are binding.